Finally, levels of some of the main mediators of EB disruption such as VEGF-A and Ang-2 have been associated with clinical severity in COVID-19 (Pine et al., 2020; Smadja et al., 2020; Rovas et al., 2021; Schmaier et al., 2021; Smadja et al., 2021). The gene discussed is VEGFA; the disease is COVID-19.